Tax News Update    Email this document    Print this document  

May 12, 2023
2023-0872

Senate Health, Education, Labor and Pensions Committee hearing on affordable insulin

On May 10, the Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing entitled, "The Need to Make Insulin Affordable for All Americans." During the hearing, committee members heard testimony from a panel of executives from the three major insulin makers and the three major pharmacy benefit managers (PBMs) in the US in advance of a May 11 markup of bills that include PBM reforms and proposals to increase access to generic drugs.

During the hearing, there was bipartisan frustration with the high cost of prescription drugs in the US compared with other developed nations, as well as bipartisan frustration about the role PBMs play in drug costs. However, several Republican committee members, including Sen. Rand Paul (R-KY), raised concerns about the unintended consequences of the legislation before the committee.

In their testimony and in response to questions, the drugmaker executives defended their approach to pricing and asked Congress to address misaligned financial incentives elsewhere in the health care industry that can prevent patients from accessing the lowest cost product. Meanwhile, PBM executives criticized drugmakers for setting high prices and urged Congress to pass bills to increase competition in the prescription drug market.

More information is available here.

Additional information is also available in the attached Tax Alert.

———————————————

Contact Information
For additional information concerning this Alert, please contact:
 
Washington Council Ernst & Young
   • Heather Meade (heather.meade@ey.com)
   • Heather Bell (heather.bell@ey.com)

———————————————
ATTACHMENT

Hearing on affordable insulin

 

The information contained herein is general in nature and is not intended, and should not be construed, as legal, accounting or tax advice or opinion provided by Ernst & Young LLP to the reader. The reader also is cautioned that this material may not be applicable to, or suitable for, the reader's specific circumstances or needs, and may require consideration of non-tax and other tax factors if any action is to be contemplated. The reader should contact his or her Ernst & Young LLP or other tax professional prior to taking any action based upon this information. Ernst & Young LLP assumes no obligation to inform the reader of any changes in tax laws or other factors that could affect the information contained herein.

 

Copyright © 1996 – 2024, Ernst & Young LLP

 

All rights reserved. No part of this document may be reproduced, retransmitted or otherwise redistributed in any form or by any means, electronic or mechanical, including by photocopying, facsimile transmission, recording, rekeying, or using any information storage and retrieval system, without written permission from Ernst & Young LLP.

 

EY US Tax News Update Master Agreement | EY Privacy Statement